Cargando…

MAFLD Criteria Guide the Subtyping of Patients with Fatty Liver Disease

BACKGROUND AND AIMS: Metabolic associated fatty liver disease (MAFLD) is diagnosed in patients with hepatic steatosis when they have the following three metabolic conditions: obesity/overweight, diabetes and metabolic dysregulation, either alone or in combination. There is no clarity whether subtype...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Jiaofeng, Ou, Weijie, Wang, Mingfang, Singh, Medha, Liu, Yuxiu, Liu, Shiying, Wu, Yinlian, Zhu, Yueyong, Kumar, Rahul, Lin, Su
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881793/ https://www.ncbi.nlm.nih.gov/pubmed/33603515 http://dx.doi.org/10.2147/RMHP.S285880

Ejemplares similares

MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis
por: Huang, Jiaofeng, et al.
Publicado: (2021)

Circadian Misalignment Rather Than Sleep Duration is Associated with MAFLD: A Population-Based Propensity Score-Matched Study
por: Weng, Zhiyuan, et al.
Publicado: (2021)

Serum high-sensitive C-reactive protein is a simple indicator for all-cause among individuals with MAFLD
por: Huang, Jiaofeng, et al.
Publicado: (2022)

Fatty liver disease reverses the obesity paradox in chronic kidney disease stages 3–5: A follow‐up study of NHANES III
por: Huang, Jiaofeng, et al.
Publicado: (2022)

Validation of Non-invasive Fibrosis Scores for Predicting Advanced Fibrosis in Metabolic-associated Fatty Liver Disease
por: Chen, Xiaoning, et al.
Publicado: (2022)

Is Toxoplasma gondii infection correlated with nonalcoholic fatty liver disease?- a population-based study
por: Huang, Jiaofeng, et al.
Publicado: (2018)

Procalcitonin and Liver Disease: A Literature Review
por: Dong, Ruolin, et al.
Publicado: (2018)

The Association between Meteorological Factors and the Prevalence of Acute-on-chronic Liver Failure: A Population-based Study, 2007–2016
por: Lin, Su, et al.
Publicado: (2019)

The Risk of Acute Kidney Injury in Hepatitis B Virus-Related Acute on Chronic Liver Failure with Tenofovir Treatment
por: Zhang, Kai, et al.
Publicado: (2020)

Serum interleukin-6 in the diagnosis of bacterial infection in cirrhotic patients: A meta-analysis
por: Wu, Yinlian, et al.
Publicado: (2016)

Syphilitic hepatitis: a case report and review of the literature
por: Huang, Jiaofeng, et al.
Publicado: (2019)

Authors response to correspondence regarding paper entitled Syphilitic hepatitis: a case report and review of the literature
por: Huang, Jiaofeng, et al.
Publicado: (2020)

Evaluating the global, regional, and national impact of syphilis: results from the global burden of disease study 2019
por: Chen, Tao, et al.
Publicado: (2023)

Antiviral Therapy in Chronic Hepatitis B With Mild Acute Exacerbation
por: Lin, Su, et al.
Publicado: (2017)

Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD
por: Chen, Jie, et al.
Publicado: (2023)

The association between vitamin D-related gene polymorphisms and hepatitis B virus-related liver cirrhosis
por: Wu, Jiali, et al.
Publicado: (2020)

From NAFLD to MAFLD: a “redefining” moment for fatty liver disease
por: Zheng, Kenneth I., et al.
Publicado: (2020)

Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis
por: Wang, Xiaolin, et al.
Publicado: (2022)

Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD)
por: Subramanian, Pallavi, et al.
Publicado: (2022)

The bidirectional impacts of alcohol consumption and MAFLD for progressive fatty liver disease
por: Kulkarni, Anand V., et al.
Publicado: (2023)

Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD)
por: Guo, Qin, et al.
Publicado: (2023)

Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update
por: Barchetta, Ilaria, et al.
Publicado: (2020)

Lead exposure as a causative factor for metabolic associated fatty liver disease (MAFLD) and a lead exposure related nomogram for MAFLD prevalence
por: Yang, Chenyu, et al.
Publicado: (2022)

Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver
por: Kaya, Eda, et al.
Publicado: (2022)

Editorial: The NAFLD-MAFLD conundrum
por: Dalbeni, Andrea, et al.
Publicado: (2023)

Increased risk of incident diabetes in patients with MAFLD not meeting the criteria for NAFLD
por: Park, So Hee, et al.
Publicado: (2023)

Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD)
por: Buzova, Diana, et al.
Publicado: (2020)

Curcumin and Biochemical Parameters in Metabolic-Associated Fatty Liver Disease (MAFLD)—A Review
por: Różański, Gracjan, et al.
Publicado: (2021)

Function of the endolysosomal network in cholesterol homeostasis and metabolic-associated fatty liver disease (MAFLD)
por: Vos, Dyonne Y., et al.
Publicado: (2021)

Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
por: Prasoppokakorn, Thaninee, et al.
Publicado: (2021)

MAFLD: what 2 years of the redefinition of fatty liver disease has taught us
por: Grabherr, Felix, et al.
Publicado: (2022)

New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk
por: Yang, Keungmo, et al.
Publicado: (2023)

Impact on Prevalence of the Application of NAFLD/MAFLD Criteria in Overweight and Normal Weight Patients
por: Ordoñez-Vázquez, Ana Luisa, et al.
Publicado: (2022)

Uncovering Actions of Type 3 Deiodinase in the Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
por: Marschner, Rafael Aguiar, et al.
Publicado: (2023)

The Asia Pacific Pediatric Association (APPA) position statement on the MAFLD definition of fatty liver disease
por: Memon, Iqbal A., et al.
Publicado: (2023)

Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment
por: Sangro, Paloma, et al.
Publicado: (2023)

Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—A Condition Associated with Heightened Sympathetic Activation
por: Carnagarin, Revathy, et al.
Publicado: (2021)

Fat: Quality, or Quantity? What Matters Most for the Progression of Metabolic Associated Fatty Liver Disease (MAFLD)
por: Estévez-Vázquez, Olga, et al.
Publicado: (2021)

Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science
por: Fouad, Yasser, et al.
Publicado: (2022)

Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways
por: Badmus, Olufunto O., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o9lj0sokcphkii7jbpkc5b14v0